IDH1 and acute myeloid leukemia: On a similar note, the study by Schmalbrock et al. using whole-exome sequencing (WES) of samples from patients with AML undergoing midostaurin treatment revealed enrichment of several mutated genes at disease progression, including WT1, NRAS, KRAS, and IDH1.